Latest Breaking News On - Hans vitzthum - Page 7 : comparemela.com

CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels

Additional data presented at The International Liver Congress™ 2023 show clinical risk factors for PBC disease progression present in a broader population of UDCA-treated PBC. | June 21, 2023

United statesHans vitzthumInternational liver congressEuropean medicines agencyDrug administrationPrnewswire cymabay therapeutics incCymabay therapeutics incExchange commissionLifesci advisorsBay therapeuticsEuropean associationNovel pathwaysPriority medicinesAnnual reportRelations contactSci advisors

CymaBay Therapeutics to Present New Data Highlighting Seladelpar s Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023

/PRNewswire/ CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.

United statesTheresa dolgeKris kowdleyCharles mcwherterChristopherl bowlusMarlynj mayoJohnm vierlingDouglasw selingerGideonm hirschfieldCharlesa mcwherterGideon hirschfieldHans vitzthumMarye standenDavide jonesYun jung choiAndrease kremer

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

CAMBRIDGE, Mass., June 07, 2023 Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal. | June 7, 2023

New yorkUnited statesUnited kingdomKarin hellsvikHans vitzthumMichael lampeAdrian gottschalkFoghorn therapeutics incGoldman sachsTherapeutics incMarriott marquisWaldorf astoria monarch beach resort clubGene trafficChief executiveAnnual global healthcare conferenceWaldorf astoria monarch beach resort

Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients

- Plan to Initiate a Phase 1 Study of FHD-286 in Combination with Decitabine or Cytarabine in Relapsed and/or Refractory AML Patients in Q3’2023 - Clinical and Pre-Clinical. | June 5, 2023

United kingdomUnited statesKarin hellsvikMartin tallmanEytan steinHans vitzthumMichael lampeAdrian gottschalkTherapeutics incCompany annual report on formExchange commissionDrug administrationFoghorn therapeutics incProgram for drug development in leukemiaLeukemia servicePre clinical data suggest

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesSarah kielyRobert stanislaroHans vitzthumGerard platenburgExchange commissionWall streetPeptide therapeuticsInnovative editing oligonucleotidesAddress liver originatedChief scientific officerOligonucleotide discoveryAdenosine deaminase acting